A. Glacetbernard et al., A RANDOMIZED, DOUBLE-MASKED STUDY ON THE TREATMENT OF RETINAL VEIN OCCLUSION WITH TROXERUTIN, American journal of ophthalmology, 118(4), 1994, pp. 421-429
Hemorheologic factors probably play a role in the pathogenesis and pro
gnosis of retinal vein occlusion. Accordingly, we designed a prospecti
ve, randomized, double-masked study to evaluate the effect of troxerut
in, a theologic drug, on retinal vein occlusion. Fifty-three patients
were included, 27 with central retinal vein occlusion and 26 with bran
ch retinal vein occlusion. They were randomly assigned for treatment w
ith either troxerutin or a placebo. All subjects were similar in age,
gender, associated diseases, hemorheologic values, and clinical severi
ty of the retinal vein occlusion. At the end of follow-up, members of
the troxerutin-treated group, as compared with the placebo group, show
ed significant improvement in visual acuity (P = .03), macular thresho
ld (P = .01), retinal circulation times (P = .04), and macular edema (
P = .05). Furthermore, they had diminished progression of ischemia (P
= .05) and decreased red blood cell aggregability (P = .006) when comp
ared with the controls. These encouraging preliminary results obtained
with a theologic treatment attest to the pathogenic role of blood vis
cosity in retinal vein occlusion and suggest that a large-scale random
ized study should be conducted.